<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191734</url>
  </required_header>
  <id_info>
    <org_study_id>TP0112</org_study_id>
    <nct_id>NCT03191734</nct_id>
  </id_info>
  <brief_title>French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue</brief_title>
  <official_title>French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PROCEPT BioRobotics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PROCEPT BioRobotics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm, multi-center prospective clinical trial to determine the safety and effectiveness&#xD;
      of the AQUABEAM System in the treatment of benign prostatic hyperplasia (BPH) in men 45 to 80&#xD;
      years of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2017</start_date>
  <completion_date type="Actual">January 7, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AQUABEAM System Effectiveness: IPSS total score change</measure>
    <time_frame>6 Months Post-op</time_frame>
    <description>IPSS total score change from baseline to 6 Month</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>AQUABEAM System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQUABEAM System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AQUABEAM System</intervention_name>
    <description>Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.</description>
    <arm_group_label>AQUABEAM System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has diagnosis of lower urinary tract symptoms due to benign prostatic&#xD;
             enlargement causing bladder outlet obstruction.&#xD;
&#xD;
          -  History of inadequate response, contraindication or refusal to medical therapy for&#xD;
             BPH.&#xD;
&#xD;
          -  Age from 45 through 80 years.&#xD;
&#xD;
          -  Prostate volume between 30mL and 80mL by transrectal ultrasound (TRUS) measured at&#xD;
             baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 42.&#xD;
&#xD;
          -  IPSS total score &lt;12.&#xD;
&#xD;
          -  History of prostate cancer or clinically significant elevated PSA value.&#xD;
&#xD;
          -  History of bladder cancer actively treated within 2 years prior to the surgical&#xD;
             procedure.&#xD;
&#xD;
          -  Bladder calculus or clinically significant bladder diverticulum (e.g., pouch size &gt;20%&#xD;
             of full bladder size).&#xD;
&#xD;
          -  Active infection, including urinary tract infection within 72 hours of the treatment&#xD;
             procedure.&#xD;
&#xD;
          -  Prostatitis treated with antibiotics within 1 year of the surgical procedure.&#xD;
&#xD;
          -  Subject ever diagnosed with urethral stricture, meatal stenosis, or bladder neck&#xD;
             contracture, or has history of damage to external urinary sphincter.&#xD;
&#xD;
          -  Subject has current diagnosis of stress urinary incontinence that requires treatment&#xD;
             or daily pad or device use.&#xD;
&#xD;
          -  Clinically significant abnormal serum creatinine measured within 30 days of treatment.&#xD;
&#xD;
          -  Maximum urinary flow rate (Qmax) &gt;15 mL/s or PVR &gt; 300 mL measured by uroflowmetry&#xD;
             test at baseline.&#xD;
&#xD;
          -  Subject has been catheterized due to retention within 14 days prior to the surgical&#xD;
             procedure.&#xD;
&#xD;
          -  Subject has a history of intermittent self-catheterization.&#xD;
&#xD;
          -  Previous prostate surgery or history of other lower urinary tract surgery such as e.g.&#xD;
             urinary diversion, artificial urinary sphincter or penile prosthesis&#xD;
&#xD;
          -  Subjects on anticoagulants or antiplatelet (if medication cannot be stopped before and&#xD;
             after procedure) or known coagulopathy (except aspirin below 100mg/d)&#xD;
&#xD;
          -  Any severe illness or psychiatric condition that would prevent study completion or&#xD;
             confound study results.&#xD;
&#xD;
          -  Subject taking systemic immune-suppressants including corticosteroids; unable to&#xD;
             withhold non- steroidal anti-inflammatory agents (NSAIDs, including aspirin) for 3-5&#xD;
             days prior to treatment except for low dose aspirin (e.g. less than 100mg).&#xD;
&#xD;
          -  Participants using medications specifically for bladder muscle problems (e.g.,&#xD;
             irritability). Use of medications with anticholinergic or similar properties is&#xD;
             allowable provided the patient does not have documented adverse urinary side effects&#xD;
             from these medications.&#xD;
&#xD;
          -  Participating in another investigational study that could affect responses to the&#xD;
             study device.&#xD;
&#xD;
          -  Subject is unwilling to accept a transfusion should one be required.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurelien Descazeaud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Régional Universitaire de Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lower Urinary Tract Symptoms (LUTS)</keyword>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>AQUABEAM</keyword>
  <keyword>Aquablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

